Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Binary biotech event live now: early positive “go” in Phase 3 CAPTIVATE interim responder analysis with detailed data discussion/webcast scheduled 2026-03-09–03-10. Stock is up ~40% over 21 days with a 12% intraday jump on the interim news, indicating strong speculative interest and a high-probability volatility window for outsized moves over the next few days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: • Uptrend intact • Breakout surge • Near resistance Support Level: $100.00 Resistance Level: $105.5-$105.8 DNTH has trended higher over the last month, with a breakout surge on 2026-07-17 and continued higher lows, but it is now consolidating just below resistance near $105.5-$105.8 while $100 remains key support.
Sentiment & News
Key News Insights: • Phase 3 start • Lead program advance • Routine equity grants Dianthus Therapeutics advanced its lead autoimmune program by initiating the Phase 3 EMERGE trial of claseprubart in generalized myasthenia gravis, alongside routine hiring-related equity grants.
AI Summary
DNTH has shifted from a promising biotech concept to a binary late-stage execution story, with EMERGE Phase 3 in gMG now the main value driver and de-risking event, but the lack of revenue, ongoing dilution pressure, and a long wait to 2H28 data make the recent re-rating vulnerable if execution falters or $100 support breaks.
Description
Dianthus Therapeutics is a clinical‑stage biotechnology firm developing monoclonal antibody therapies for severe autoimmune and inflammatory diseases. Its lead candidate, DNTH103, is in Phase 1 clinical trials for generalized myasthenia gravis and several immune‑mediated neuropathies. The company was founded in 2015 and is based in New York.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 9 | Mar 16 | DNTH | Dianthus Therapeutics, Inc. | Binary biotech event live now: early positive “go” in Phase 3 CAPTIVATE interim responder analysis with detailed data discussion/webcast scheduled 2026-03-09–03-10. Stock is up ~40% over 21 days with a 12% intraday jump on the interim news, indicating strong speculative interest and a high-probability volatility window for outsized moves over the next few days. | Closed | -1.6% |